Spots Global Cancer Trial Database for P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer
Official Title: Expression of the P16 Protein in Serous Papillary Endometrial Cancer, and Its Clinical and Prognostic Significance
Study ID: NCT01267357
Conditions
Interventions
Study Description
Brief Summary: P16 is a tumor suppressor protein implicated in serous papillary endometrial carcinoma. Evidence from previous trials indicates that it may be used as a diagnostic biomarker distinguishing this disease from endometrioid endometrial cancer. Additional evidence points to its prognostic value. The current study will evaluate p16 both as a diagnostic tool for serous papillary endometrial cancer and as a prognostic biomarker. following anonymization, histology blocks will be microtomed and stained for P16 and P53 proteins. Blocks from endometrioid endometrial cancer will be used as a control group.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Rambam Medical Center, Haifa, , Israel
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
